Spyre Therapeutics, Inc.
SYRE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SYRE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SYRE
Spyre Therapeutics, Inc. (SYRE) is a clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease (IBD) and other inflammatory conditions, with a pipeline of product candidates including SPY003, SPY002, and SPY072.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 8 clinical trials · 4 catalysts for Spyre Therapeutics, Inc..
Spyre Therapeutics, Inc. (SYRE) is a clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease (IBD) and other inflammatory conditions, with a pipeline of product candidates including SPY003, SPY002, and SPY072.
- Spyre is a clinical-stage biotechnology company with no approved products or revenue from commercial sales [sec_mda · as of 2026-05-05].
- As of June 30, 2026, the company reported cash and equivalents of $162.0M, shareholders' equity of $715.2M, and a net loss of $36.2M for the quarter [sec].
- The company raised approximately $435.2 million in net proceeds from a public underwritten offering in April 2026 [sec_mda · as of 2026-08-04].
- Spyre is advancing multiple candidates into Phase 2 trials, with readouts expected for RA (September 2026), SPY072 (December 2026), and SPY002 (December 2026) [catalyst].
- Since inception through December 31, 2025, the company has raised approximately $1.6 billion in gross proceeds and had an accumulated deficit of $1.1 billion as of September 30, 2025 [sec_mda · as of 2026-02-19].
What works
- Spyre's pipeline targets a large market (IBD) with candidates designed for improved convenience (e.g., quarterly or twice-yearly maintenance dosing) that could set a new standard of care [sec · filed 2025-11-04].
- The company has raised substantial capital, including $435.2M in April 2026, providing resources to fund operations for at least one year [sec_mda · as of 2026-08-04].
- Multiple Phase 2 trials are planned or underway, with topline readouts expected in late 2026, offering potential catalysts for value inflection [catalyst].
What to weigh
- Spyre has a history of significant operating losses and an accumulated deficit of $1.1 billion as of September 30, 2025, with no assurance of future profitability [sec_mda · as of 2026-02-19].
- The company will need additional financing to fund further development and commercialization, and failure to obtain it could materially affect operations [sec_mda · as of 2026-05-05].
- All product candidates are in clinical or preclinical stages; there is no guarantee of regulatory approval or commercial success [sec · filed 2025-11-04].
From the filings
Quoted directly from source documents.
Spyre has no revenue from product sales and expects losses to increase.
“we have generated operating losses since our inception and have not generated any revenue from the commercial sale of any products.”
SEC MD&A · May 5, 2026
Spyre raised $435.2M in net proceeds from a public offering in April 2026.
“April 2026, we raised an additional approximately $435.2 million in net proceeds from a public underwritten offering of our common stock.”
SEC MD&A · August 4, 2026
Spyre has an accumulated deficit of $1.1 billion as of September 30, 2025.
“As of September 30, 2025, we had an accumulated deficit of $1.1 billion.”
SEC MD&A · November 4, 2025
Spyre's SPY003 candidate may offer quarterly or twice-yearly dosing.
“potential for a quarterly or twice yearly maintenance dosing profile that may set a new standard of care for inflammatory bowel disease”
SEC filings · November 4, 2025
Catalyst timeline
- 2026-09-01 · Phase 2 Start: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Asse — Initiation of a Phase 2 proof-of-concept trial; enrollment status is 'Not yet recruiting' as of the catalyst filing.
- 2026-09-30 · Phase 2 Readout: RA — Topline data from a Phase 2 trial in rheumatoid arthritis expected; results will inform efficacy and safety.
- 2026-12-31 · Phase 2 Readout: SPY072 — Topline data from a Phase 2 trial of SPY072 expected; outcome will guide further development.
- 2026-12-31 · Phase 2 Readout: SPY002 — Topline data from a Phase 2 trial of SPY002 expected; results will be a key pipeline milestone.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Spyre has no commercial products and no revenue from product sales; profitability is uncertain [sec_mda · as of 2026-05-05].
- Need for future financing — The company will require additional capital to fund R&D and commercialization; failure to secure it could harm operations [sec_mda · as of 2026-05-05].
- Clinical development risks — All candidates are in early stages; Phase 2 trials may fail to meet endpoints, delaying or halting development [sec · filed 2025-11-04].
- Accumulated deficit and losses — Accumulated deficit of $1.1B as of Sep 2025; net loss of $36.2M in Q2 2026 [sec_mda · as of 2025-11-04] [sec].
What to watch
- Phase 2 topline readout for RA candidate expected September 30, 2026 [catalyst].
- Phase 2 topline readouts for SPY072 and SPY002 expected by December 31, 2026 [catalyst].
- Initiation of Phase 2 trial for hidradenitis suppurativa (NCT07766005) on September 1, 2026 [catalyst].
- Cash runway and any additional financing needs, given the company's expectation to fund operations for at least one year from latest filing [sec_mda · as of 2026-05-05].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Spyre Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Spyre Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
47.4 months
D/E 0.07
Lead: Phase 2
4 candidates
4 upcoming, next in ~2d
0 buys · 54 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
196
Total value held
$4.16B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 11,781,024 | $594.2M |
| perceptive advisors llc | 7,566,450 | $381.7M |
| vanguard capital management llc | 6,114,802 | $308.4M |
| blackrock, inc. | 5,521,221 | $278.5M |
| rtw investments, lp | 4,171,996 | $210.4M |
| remedium capital partners, llc | 3,363,558 | $169.7M |
| janus henderson group plc | 3,312,328 | $167.2M |
| driehaus capital management llc | 2,790,785 | $140.8M |
| state street corp | 2,607,031 | $131.5M |
| commodore capital lp | 1,912,380 | $96.5M |
Showing top 10 of 196 institutional holders of Spyre Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 14.3%
- Days to cover
- 12.6
- Shares short
- 10,435,737
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SYRE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Spyre Therapeutics, Inc.?
Spyre Therapeutics, Inc. (SYRE) is a clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease (IBD) and other inflammatory conditions, with a pipeline of product candidates including SPY003, SPY002, and SPY072.
What is Spyre Therapeutics, Inc.'s lead drug candidate?
Spyre Therapeutics, Inc.'s most advanced tracked candidate is SPY001 (Phase 2) for Ulcerative Colitis.
What is Spyre Therapeutics, Inc.'s next catalyst?
Spyre Therapeutics, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Asse" — expected September 1, 2026.
Who is the CEO of Spyre Therapeutics, Inc.?
Dr. Cameron Turtle DPHIL, Ph.D. is the chief executive officer of Spyre Therapeutics, Inc. (SYRE).
Where is Spyre Therapeutics, Inc. headquartered?
Spyre Therapeutics, Inc. (SYRE) is headquartered in Waltham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.